Anti-EGFR antibody conjugated silica nanoparticles as probes for lung cancer detection

13Citations
Citations of this article
25Readers
Mendeley users who have this article in their library.
Get full text

Abstract

A well-designed nanosystem [anti-epidermal growth factor receptor-MB-encapsulated thiol-terminated silica nanoparticles (EGFR/MB-SHSi) complexes] containing silica nanoparticles and near-infrared fluorescence dye (NIRF) methylene blue (MB) was established as a tumor-targeted probe for potential lung cancer detection. The anti-EGFR/MB-SHSi complexes exhibited desirable and homogenous particle size, high bovine serum albumin stability, low hemolytic activity, neutral surface charges and negligible cytotoxicity in vitro. Furthermore, the results of confocal laser scanning microscopy and flow cytometry confirmed that the EGFR-targeted function induced high and specific cellular uptake of anti-EGFR/MB-SHSi complexes. In vivo investigation of nude mice bearing A549 tumor xenografts revealed that anti-EGFR/MB-SHSi complexes possessed strong tumor target ability. These observations indicated that anti-EGFR/MB-SHSi complexes may be a safe and tumor-targeting probe for the detection of cancer.

Cite

CITATION STYLE

APA

Wan, J., Wu, W., Zhang, R., Liu, S., & Huang, Y. (2017). Anti-EGFR antibody conjugated silica nanoparticles as probes for lung cancer detection. Experimental and Therapeutic Medicine, 14(4), 3407–3412. https://doi.org/10.3892/etm.2017.4988

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free